Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

Shares of Trinity Biotech stock opened at $0.69 on Friday. The firm has a market cap of $12.37 million, a price-to-earnings ratio of -0.30 and a beta of 1.20. The business has a 50-day moving ...

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

European equities traded in the US as American depositary receipts were lower late Wednesday morning, declining 0.36% to 1,442.32 on the S&P Europe Select ADR Index. From continental Europe, the ...

Trinity Biotech received Nasdaq notices for non-compliance with bid price and market value requirements, with 180 days to address deficiencies. Trinity Biotech plc, a biotechnology company ...

Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management, announced it has secured an additional $4 million in debt financing from Perceptive Advisors.

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

Trinity Biotech plc DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and ...